Novel strategies for the treatment of sepsis
Top Cited Papers
- 1 May 2003
- journal article
- review article
- Published by Springer Nature in Nature Medicine
- Vol. 9 (5), 517-524
- https://doi.org/10.1038/nm0503-517
Abstract
The history of therapeutic interventions in clinical trials for sepsis has been referred to as the "graveyard for pharmaceutical companies." That is now set to change, as research provides hope for new approaches that will be therapeutically effective in humans with sepsis.Keywords
This publication has 79 references indexed in Scilit:
- Risks and Benefits of Activated Protein C Treatment for Severe SepsisNew England Journal of Medicine, 2002
- C5a receptor and thymocyte apoptosis in sepsisThe FASEB Journal, 2002
- Migration-Inhibitory Factor Gene-Deficient Mice Are Susceptible to CutaneousLeishmania majorInfectionInfection and Immunity, 2001
- Confirmatory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsisCritical Care Medicine, 1998
- Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shockCritical Care Medicine, 1996
- A new approach in the treatment of hypotension in human septic shock by NG-monomethyl-L-arginine, an inhibitor of the nitric oxide synthetaseIntensive Care Medicine, 1993
- The anaphylatoxins C3a and C5a are vasodilators in the canine coronary vasculaturein vitro andin vivoInflammation Research, 1991
- Interleukin-1 receptor antagonist reduces mortality from endotoxin shockNature, 1990
- Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.Journal of Clinical Investigation, 1988
- Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage.Journal of Clinical Investigation, 1978